Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Crystalys Therapeutics, with $205M in funding, launches to advance a new gout treatment in early human trials.
Crystalys Therapeutics has launched with $205 million in funding to advance clinical trials for a new gout treatment, targeting the root causes of the painful inflammatory condition caused by uric acid buildup.
The investment will support early-stage human trials to assess the drug’s safety, tolerability, and effectiveness, aiming to address unmet needs in gout care.
The company, based in Ashburn, Virginia, is a private biotech focused on innovative therapies for metabolic and inflammatory diseases.
7 Articles
Crystalys Therapeutics, con $ 205M en financiamiento, se lanza para avanzar en un nuevo tratamiento de gota en los primeros ensayos en humanos.